Lung Cancer Trial, Recruiting (NCT06967532)

Lung Cancer Trial, Recruiting NCT06967532 Sponsor: Medical University of Vienna Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06967532 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer) at a certain stage (stage II, III, or stage IV with limited spread to only a few areas), confirmed through a tissue or cell sample.
People whose cancer has been assessed by a specialist medical team as suitable for surgery with the goal of curing the disease, following treatment that includes a type of therapy that helps the immune system fight cancer.
People with a good general level of physical functioning, meaning they are able to carry out daily activities with little or no limitation (confirm with trial site for exact definition).
People who have had specific scans to check the extent of their cancer, including a PET/CT scan of the body and a brain scan (MRI or CT).
People who have given written agreement to take part in the trial.

Who may not be able to join:

No exclusion criteria were listed in the official trial information. (Confirm with trial site for any additional requirements.)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +43140400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06967532

Sponsor: Medical University of Vienna

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +43140400

More information: https://clinicaltrials.gov/study/NCT06967532

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer) at a certain stage (stage II, III, or stage IV with limited spread to only a few areas), confirmed through a tissue or cell sample.
People whose cancer has been assessed by a specialist medical team as suitable for surgery with the goal of curing the disease, following treatment that includes a type of therapy that helps the immune system fight cancer.
People with a good general level of physical functioning, meaning they are able to carry out daily activities with little or no limitation (confirm with trial site for exact definition).
People who have had specific scans to check the extent of their cancer, including a PET/CT scan of the body and a brain scan (MRI or CT).
People who have given written agreement to take part in the trial.

Who may not be able to join:

No exclusion criteria were listed in the official trial information. (Confirm with trial site for any additional requirements.)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Medical University of Vienna

Registry

ClinicalTrials.gov

Start date

6 September 2024

Est. completion

1 September 2026

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Histopathological response to neoadjuvant chemo-immunotherapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov